BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

691 related articles for article (PubMed ID: 19744978)

  • 21. In vitro activity of linezolid, tigecycline, and daptomycin on methicillin-resistant Staphylococcus aureus blood isolates from adult patients, 2006-2008: stratified analysis by vancomycin MIC.
    Kao TM; Wang JT; Weng CM; Chen YC; Chang SC
    J Microbiol Immunol Infect; 2011 Oct; 44(5):346-51. PubMed ID: 21524980
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [In vitro susceptibility of methicillin-resistant Staphylococcus aureus isolates to vancomycin, teicoplanin, linezolide and daptomycin].
    Celikbilek N; Ozdem B; Gürelik FC; Güvenman S; Güner HR; Açıkgöz ZC
    Mikrobiyol Bul; 2011 Jul; 45(3):512-8. PubMed ID: 21935784
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05.
    Steinkraus G; White R; Friedrich L
    J Antimicrob Chemother; 2007 Oct; 60(4):788-94. PubMed ID: 17623693
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [The incidence and risk factors for heterogeneous vancomycin intermediate Staphylococcus aureus].
    Feng NN; Wang Q; Song YL; He LX; Zhou CM; Xie HM; Li HY
    Zhonghua Nei Ke Za Zhi; 2013 Apr; 52(4):318-22. PubMed ID: 23925360
    [TBL] [Abstract][Full Text] [Related]  

  • 25. In vitro effect of the presence of human albumin or human serum on the bactericidal activity of daptomycin against strains with the main resistance phenotypes in Gram-positives.
    Cafini F; Aguilar L; González N; Giménez MJ; Torrico M; Alou L; Sevillano D; Vallejo P; Prieto J
    J Antimicrob Chemother; 2007 Jun; 59(6):1185-9. PubMed ID: 17412725
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High vancomycin minimum inhibitory concentrations with heteroresistant vancomycin-intermediate Staphylococcus aureus in meticillin-resistant S. aureus bacteraemia patients.
    Wang JL; Lai CH; Lin HH; Chen WF; Shih YC; Hung CH
    Int J Antimicrob Agents; 2013 Nov; 42(5):390-4. PubMed ID: 24041465
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Activity of simulated serum concentrations of daptomycin versus vancomycin during the first 24h of treatment in the presence of physiological albumin concentrations against vancomycin-susceptible, -tolerant or -intermediate-resistant Staphylococcus aureus.
    Torrico M; Aguilar L; Sevillano D; Giménez MJ; Alou L; González N; Cafini F; Cleeland R; Prieto J
    Int J Antimicrob Agents; 2011 Apr; 37(4):332-8. PubMed ID: 21388792
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vancomycin MICs did not creep in Staphylococcus aureus isolates from 2002 to 2006 in a setting with low vancomycin usage.
    Alós JI; García-Cañas A; García-Hierro P; Rodríguez-Salvanés F
    J Antimicrob Chemother; 2008 Oct; 62(4):773-5. PubMed ID: 18552338
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of method-specific vancomycin minimum inhibitory concentration values and their predictability for treatment outcome of meticillin-resistant Staphylococcus aureus (MRSA) infections.
    Hsu DI; Hidayat LK; Quist R; Hindler J; Karlsson A; Yusof A; Wong-Beringer A
    Int J Antimicrob Agents; 2008 Nov; 32(5):378-85. PubMed ID: 18701261
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antimicrobial activity of daptomycin and selected comparators tested against bloodstream Staphylococcus aureus isolates from hemodialysis patients.
    Sader HS; Fritsche TR; Jones RN
    Int J Infect Dis; 2009 Mar; 13(2):291-5. PubMed ID: 18938097
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Comparative study of the susceptibility to daptomycin and other antimicrobials against Staphylococcus spp. resistant to methicillin and Enterococcus spp. using Wider, E-test, and microdilution methods].
    Gómez-Garcés JL; López-Fabal F; Burillo A; Gil Y
    Rev Esp Quimioter; 2010 Jun; 23(2):87-92. PubMed ID: 20559607
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Activity of telavancin against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) in vitro and in an in vivo mouse model of bacteraemia.
    Hegde SS; Skinner R; Lewis SR; Krause KM; Blais J; Benton BM
    J Antimicrob Chemother; 2010 Apr; 65(4):725-8. PubMed ID: 20139142
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Incidence and characteristics of vancomycin nonsusceptible strains of methicillin-resistant Staphylococcus aureus at Hershey Medical Center.
    Kosowska-Shick K; Ednie LM; McGhee P; Smith K; Todd CD; Wehler A; Appelbaum PC
    Antimicrob Agents Chemother; 2008 Dec; 52(12):4510-3. PubMed ID: 18838583
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Investigation of glycopeptide resistance in methicillin resistant staphylococcal isolates].
    Hoşgör Limoncu M; Ermertcan S; Taşli H; Kurutepe S
    Mikrobiyol Bul; 2007 Oct; 41(4):511-6. PubMed ID: 18173069
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Activity of daptomycin and selected antimicrobial agents tested against Staphylococcus aureus from patients with bloodstream infections hospitalized in European medical centers.
    Sader HS; Watters AA; Fritsche TR; Jones RN
    J Chemother; 2008 Feb; 20(1):28-32. PubMed ID: 18343740
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of reduced vancomycin susceptibility in methicillin-susceptible Staphylococcus aureus.
    Pillai SK; Wennersten C; Venkataraman L; Eliopoulos GM; Moellering RC; Karchmer AW
    Clin Infect Dis; 2009 Oct; 49(8):1169-74. PubMed ID: 19769538
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Molecular epidemiology and clinical characteristics of hetero-resistant vancomycin intermediate Staphylococcus aureus bacteremia in a Taiwan Medical Center.
    Lin SY; Chen TC; Chen FJ; Chen YH; Lin YI; Siu LK; Lu PL
    J Microbiol Immunol Infect; 2012 Dec; 45(6):435-41. PubMed ID: 22749725
    [TBL] [Abstract][Full Text] [Related]  

  • 38. In vitro activity of omiganan pentahydrochloride tested against vancomycin-tolerant, -intermediate, and -resistant Staphylococcus aureus.
    Fritsche TR; Rhomberg PR; Sader HS; Jones RN
    Diagn Microbiol Infect Dis; 2008 Apr; 60(4):399-403. PubMed ID: 18178361
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low prevalence of methicillin-resistant Staphylococcus aureus with reduced susceptibility to glycopeptides in Belgian hospitals.
    Nonhoff C; Denis O; Struelens MJ
    Clin Microbiol Infect; 2005 Mar; 11(3):214-20. PubMed ID: 15715719
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diminished vancomycin and daptomycin susceptibility during prolonged bacteremia with methicillin-resistant Staphylococcus aureus.
    Bennett JW; Murray CK; Holmes RL; Patterson JE; Jorgensen JH
    Diagn Microbiol Infect Dis; 2008 Apr; 60(4):437-40. PubMed ID: 18096352
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 35.